Amberstone and Henlius agree to develop solid-tumour T-cell engagers

Partnershipconditionally activated T-cell engager candidatesPositive

AI Analysis

Summary

Amberstone Biosciences and Shanghai Henlius Biotech have entered a partnership and licensing agreement to develop conditionally activated T-cell engager candidates for solid tumour treatment.

Importance:5/10

Sentiment:

0.50

partnershiplicensingT-cell engagersolid tumorscollaboration

Related Companies

$SLDB

Read the original article

Published by Pharmaceutical Technology on September 25, 2026 9:10 AM

Read Original